Found 8 matching trials
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
PHASE1PRIMARY OBJECTIVE
\- To evaluate the efficacy (according to the Internatio...
Location
Istituto Nazionale per lo studio e la cura dei Tumori
Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera
PHASE2The primary objective of the study was to evaluate the efficacy of Givinost...
Location
Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
PHASE2Primary objective:
To assess the safety of ITF 2357 administered once week...
Location
Presidio Ospedaliero R. Binaghi
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
PHASE2This study has the following objectives:
Primary objective:
\- To determi...
Location
Clinica Institute Fundeni.Pediatric Clinic 258 Sos. Fundeni,
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
PHASE2Primary objective:
\- To determine overall response-rate, complete respons...
Location
Department of Internal Medicine and Public Health, University of Perugia
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
PHASE2Primary Objective:
To evaluate efficacy and safety of ITF2357 in the treat...
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
PHASE2This is a multicenter, open label, long-term study testing the long-term sa...
Status
Active Not Recruiting
Location
Charite Research Organization GmbH
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
PHASE1This study has the following objectives:
Primary Objective
* To evaluate ...
Location
Istituto Nazionale per la Cura e lo Studio dei Tumori